Navigation Links
New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline
Date:6/12/2009

SCOTTSDALE, Ariz., June 12 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area (http://www.medpredict.com/website/home.aspx).

MedPredict interviewed renowned Alzheimer's disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of Neurology (AAN) conference.

"In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline," according to Jeff Berk, MedPredict's president and lead author of this report. "The panel covers active and passive immunologic approaches that hold promise in prevention of Alzheimer's disease and treatment at the earliest stages of dementia."

"The panelists rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau phosphorylation inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, histone deacetylases (HDACs), SIRT-1, metal chelators and drugs like Dimebon, specifically designed to enhance mental function," says Berk. "They also update the progress coming out of ADNI, the Alzheimer's Disease Neuroimaging Initiative, and describe how some amazing diagnostic tools have now been incorporated into the pivotal trials of these exciting therapeutics."

Companies/partnerships discussed in this report: Abbott, Allon, Astellas/CoMentis, AstraZeneca/Banner, AstraZeneca/Takeda, AstraZeneca/Targacept, Avid, Baxter, Bayer-Schering/Avid Radiopharmaceuticals, Boehringer Ingelheim/Ablynx, Bristol-Myers Squibb, Elan/Transition Therapeutics/AZ, Elan/Wyeth, Envivo, Eisai, Forest/Merz/Lundbeck/Daiichi-Sankyo, GE Healthcare, GlaxoSmithKline, Lilly, Lilly/Elan, Link, Myriad, Novartis, Oligomerix, Pfizer, Pfizer/Medivation, Prana, Roche/Memory, Satori, TauRx, TauTaTis, Transtech, and Wyeth.

The full report may be purchased by contacting MedPredict.

About MedPredict

MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
3. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
4. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
5. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
6. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
7. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
8. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
9. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
10. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
11. BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After Youve Eaten Asparagus?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SOUTH PLAINFIELD, N.J. , Feb. 12, 2016 ... today announced the second annual STRIVE (Strategies to ... for Duchenne muscular dystrophy (DMD). STRIVE provides funds ... collaborative programs that will make meaningful contributions to ... education or fostering development of future patient advocates. ...
(Date:2/11/2016)... SAN DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: ... year ended December 31, 2015. --> ... reported a net loss of $29.3 million, or $0.34 loss per ... loss per share for the same period in 2014. For the ... of $88.9 million, or $1.05 loss per share, as compared to ...
(Date:2/11/2016)...  Bioethics International, a not-for-profit organization focused on the ethics ... made accessible to patients around the world, today announced that ... publication of the Good Pharma Scorecard an ... as one of BMJ Open ,s ,Most Popular Articles, ... most frequently read. Ed Sucksmith , assistant editor ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... on the development and manufacture of biopharmaceuticals and therapeutics, announces an agreement ... 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations and ...
Breaking Biology Technology:
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... MedNet,s significant achievements are the result of the company,s ... iMedNet eClinical , it,s comprehensive, easy-to-use and ... --> Key MedNet growth achievements in ...
Breaking Biology News(10 mins):